TCT 2019: BD, VIVA Data Show Lower Paclitaxel Mortality Risk
Executive Summary
BD said an independent Lutonix review found no significant link to deaths, while further meta-analysis from trade group VIVA showed a decline in the risk. Both studies were unveiled at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
You may also be interested in...
VIVA 2019: 4-Year Data Shows Success For Medtronic’s In.Pact Admiral DCB
An ongoing trial of Medtronic’s In.Pact Admiral paclitaxel-coated balloon found a four-year survival rate in line with what would be expected for the patient population and a relatively low rate of complications.
Newer Data Fades Paclitaxel Risk, Physician Group Says
A meta-analysis that seemed to show an increased mortality risk tied to paclitaxel-coated balloons and stents sent shockwaves through the device industry last year. But a more complete data review funded by nonprofit group VIVA Physicians may show that the issue has been overestimated.